back to Canada directory
canada clinical guidance

Lipid modification: primary + secondary prevention (statins)

A Canadian clinical summary of lipid modification: primary + secondary prevention (statins), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by 2021 guidelines for the management of dyslipidemia for cardiovascular disease prevention. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CCS lipids

Source-attributed clinical priorities

  • Estimate cardiovascular risk using the CCS approach and identify clinical atherosclerotic disease or other statin-indicated conditions.
  • Use statins as foundational pharmacotherapy when indicated, with adherence, tolerability and secondary causes reviewed before escalation.
  • Apply CCS thresholds for intensification only from the current guideline and verify public-plan coverage for non-statin agents locally.
  • Discuss absolute cardiovascular benefit, adverse effects, adherence and patient priorities before intensifying therapy.
sources for this section:CCS lipids

Practical assessment and management workflow

1
Obtain a complete lipid profile and identify secondary causes and established atherosclerotic disease.
2
Calculate Framingham risk only when no statin-indicated condition already establishes treatment.
3
Start and optimize statin therapy, then apply CCS intensification thresholds to residual risk.
4
Repeat lipids to assess response and adherence and investigate clinically significant adverse effects.
sources for this section:CCS lipids

Safety, red flags and urgent escalation

  • Do not use a risk calculator during an acute illness or as a substitute for clinical disease.
  • Review pregnancy, liver disease, interacting medicines and previous muscle toxicity before treatment.
  • Confirm provincial coverage before promising access to ezetimibe, PCSK9 therapy or inclisiran.
sources for this section:CCS lipids

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CCS lipids

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CCS lipids

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Cardiovascular Society2021 guidelines for the management of dyslipidemia for cardiovascular disease preventionaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.